Curebase is a company that provides in-house decentralized clinical trial (DCT) services, and its latest partnership looks to offer additional patient monitoring tools to trial sponsors.
The collaboration with Redenlab will see speech and language biometrics be added to its virtual trial tools to aid in decision-making in clinical trials for specific neurological conditions.
Redenlab’s digital speech platform offers objective measurement and analysis of communication ability to determine whether pharmaceutical treatments are proving effective in patients. Curebase plans to incorporate this capacity as a way to add speech analytics to pharmaceutical studies where appropriate.
According to Curebase, this will provide a more comprehensive monitoring approach in trials, whilst also improving patient safety and well-being.
Redenlab states that the data capture can be managed through desktop, mobile, and web applications. The data is then stored and accessed through a cloud-based data portal, from which data analysis can be carried out on speech production, language and speech perception.
The analysis is able to identify specific deficits in speech performance and to monitor change in function over time. The tests can be used from preclinical to post-marketing trials of products, and is built with AWS, a HIPPA compliant system.
For sponsors, the tools can provide relevant data metrics in accordance with regulatory requirements for certain trials, Curebase stated.
Growth of DCTs
The pandemic brought with it the necessity to develop clinical trials structures that were adapted to the lockdowns experienced globally, leading to a boom in DCTs adoption.
Curebase signed several partnerships over the period to expand its range of services to facilitate a decentralized process. Last year, the company announced that it would work with AppliedVR to test the viability of virtual reality therapy in pain management.
Previously, Adam Samson, senior director of clinical operations and customer success at Curebase, spoke to Outsourcing-Pharma about the potential for digital therapeutics (DTx) to transform the healthcare system.
He said, “DTx products fill gaps within the healthcare system by providing additional options for delivering therapies to patients at scale. For example, mental health is an area where it is challenging for clinicians, given the high prevalence of related conditions, to deliver cognitive behavioral therapy to all patients who may benefit from this treatment.”